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Abstract
Alzheimer’s disease (AD) is an age-related progressive and neurodegenerative 
disorder, which is characterized by loss of memory and cognitive decline. It is the 
main cause of disability among older people. The rapid increase in the number of 
people living with AD and other forms of dementia due to the aging population rep-
resents a major challenge to health and social care systems worldwide. Degeneration 
of brain cells due to AD starts many years before the clinical manifestations become 
clear. Early diagnosis of AD will contribute to the development of effective treat-
ments that could slow, stop, or prevent significant cognitive decline. Consequently, 
early diagnosis of AD may also be valuable in detecting patients with dementia 
who have not obtained a formal early diagnosis, and this may provide them with a 
chance to access suitable healthcare facilities. An early diagnosis biomarker capable 
of measuring brain cell degeneration due to AD would be valuable. Potentially, 
electroencephalogram (EEG) can play a valuable role in the early diagnosis of AD. 
EEG is noninvasive and low cost, and provides valuable information about brain 
dynamics in AD. Thus, EEG-based biomarkers may be used as a first-line decision-
support tool in AD diagnosis and could complement other AD biomarkers.
Keywords: EEG biomarkers, AD biomarkers, slowing of EEG, decrease in EEG 
coherence, reduction in EEG complexity, detection of Alzheimer’s disease
1. Introduction
Alzheimer’s disease (AD) is an age-related progressive neurodegenerative disor-
der characterized by cognitive impairment and memory loss [1, 2] and is the leading 
cause of elderly disability [3]. AD is categorized as the sixth major cause of death 
in the United States among older people [4]. Due to the aging population, the fast 
growth in the number of individuals living with AD and other kinds of dementia is 
a major challenge for health and social care systems around the world [5]. There are 
currently more than 46.8 million people with dementia around the world with an 
annual care cost estimated at US$ 818 billion and an annual cost of US$ 2 trillion is 
projected to reach 74.7 million by 2030 [6]. It is estimated that by 2050 the number 
of people with dementia around the world will exceed 131 million, which will have 
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an enormous financial. However, many dementia sufferers are not diagnosed early 
[7, 8]. It is estimated that up to 50% of individuals with dementia may not have been 
diagnosed formally [8, 9]. In 2011, 28 million people out of 36 million people with 
dementia were not diagnosed worldwide [10].
Degeneration of brain cells due to AD begins many years before clinical 
manifestations become noticeable [5, 11–15]. Early diagnosis of AD will help 
to the development of efficient treatments that could mitigate, stop, or prevent 
significant cognitive impairment [14, 16, 17]. Early diagnosis of AD may also be 
valuable in detecting patients with dementia who have not obtained a formal early 
diagnosis, and this may provide them with a chance to access suitable healthcare 
facilities [18–20].
An early diagnosis biomarker that can measure brain cell degeneration due to 
AD would be valuable [2, 21–23]. But this may involve dealing with an extremely 
large number of individuals, as up to 50% of individuals with dementia may not 
have been diagnosed formally. Therefore, Simple, non-invasive, low-cost and 
reliable biomarkers are necessary for early diagnosis that can be accessed in clinical 
practice [5, 24, 25]. Recent guidelines support the use of biomarkers for biochemi-
cal and neuroimaging to promote AD diagnosis. AD testing of cerebral spinal fluid 
(CSF) is not commonly used in clinical practice as it involves lumbar puncture, an 
invasive procedure [2, 26, 27]. Neuroimaging is expensive, accessible only in spe-
cialized centers [28], and may not be appropriate for patients with pacemakers or 
certain implants [29]. Blood-based biomarkers have shown promising results in the 
diagnosis of AD but are not yet fully developed and there are currently no low-cost 
biosensors available for the detection of AD biomarkers in the blood [2, 24, 30].
EEG can play a potential role in early diagnosis of AD [11, 19, 20, 23, 31–33] EEG 
is non-invasive, low-cost, has a high temporal resolution, and provides valuable 
information about brain dynamics in AD [19, 20, 32, 34, 35]. The essential utility of 
EEG in detecting brain signal changes has been proved even at the preclinical stage 
of the disease [32, 36, 37]. EEG biomarkers can, therefore, be used in the diagnosis 
of AD as a first-line decision support tool [11, 34] and could supplement other AD 
biomarkers [25].
As a consequence of brain cell damage that affects brain activity, AD is charac-
terized by memory loss and cognitive impairment [37]. AD leads changes in EEG 
characteristics [34, 37, 38] and EEG analysis may provide useful information about 
brain dynamics caused by AD [19, 20, 32, 34]. The most characteristic features in 
EEG caused by AD are slowing of EEG, a decrease in EEG coherence, and reduction 
in EEG complexity [32–34, 36–39]. These changes in the EEG can be quantified as 
a biomarker of AD. In order to quantify EEG changes as AD biomarkers, a range 
of linear and nonlinear techniques are being developed [40, 41]. AD biomarkers 
based on EEG slowing and reducing EEG coherence are often produced using linear 
methods of analysis (i.e. EEG signal spectral analysis) [36, 42, 43]. While biomark-
ers derived from the EEG complexity analysis are based on non-linear methods (e.g. 
entropy methods, fractal dimension, and Lempel-Ziv complexity) [44–47].
This chapter describes research into the development of EEG biomarkers that 
detect AD based on analysis of changes in the EEG. These changes can be quantified 
as a biomarker of AD. The most characteristic features in EEG caused by AD are 
slowing of EEG, a decrease in EEG coherence, and reduction in EEG complexity 
were reviewed in this chapter.
The chapter is arranged as follows. In Section 2, the EEG characteristic features 
of AD detection. In Section 3, the discussions are presented and the conclusions are 
presented in Section 4.
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2. EEG characteristic features of AD detection
The most characteristic features evident in an EEG that detects AD are slowing 
of the EEG, a reduction in EEG complexity, and a decrease in EEG coherence [32, 
34, 36–39]. These changes can thus be quantified as biomarkers of AD. EEG based 
biomarkers can therefore be divided into three main categories: the slowing of the 
EEG, reduction in complexity, and a decrease in the coherence between cortical 
regions [32–34, 36–39, 48]. The slowing of the EEG and reduction in complexity 
were reviewed in this chapter.
2.1 Reduction in EEG complexity
Approaches to EEG complexity showed promising results in the diagnosis of AD 
[11, 34, 49] and seemed suitable for the diagnosis of AD [37, 50, 51]. Complexity is a 
measure of how random the dynamic behavior of a particular sequence is [52]. The 
cortical regions of the brain are spontaneously fired, and this dynamic behavior 
is complex [53, 54]. AD causes a reduction in the neuronal activity of the brain 
[55] resulting in a decreased ability to process information [56–58] which may be 
reflected in EEG signals [55]. Several studies have investigated EEG complexity as 
a potential AD biomarker using whole EEG record with the objective of achiev-
ing a high performance. Given the association of EEG activities (e.g., alpha, delta 
activities) with AD, Al-nuaimi et al. [49] they proved that the derivation of EEG 
complexity based on EEG activities should lead to enhanced performance. This 
reduction can be measured using different methods e.g., Tsallis entropy (TsEn) [34, 
59, 60], Higuchi Fractal Dimension (HFD) [61], and Lempel Ziv Complexity (LZC) 
[41, 47]. Consequently, EEG complexity can potentially be a good biomarker for 
AD diagnosis [37] as AD patients exhibit a significant reduction in EEG complexity 
[37–39, 48, 55, 62, 63].
In particular, TsEn approach has been shown to be one of the most promising 
information-theoretic methods for quantifying EEG complexity [34, 59, 60, 64, 
65]. It has also been shown to be a reliable analysis tool to use with working memory 
tasks. Its capacity for rapid computation may serve as the basis for real-time deci-
sion support tools for diagnosing AD [34, 59, 65–67]. Sneddon et al. [68] analyzed 
EEG TsEn and found that it was capable of detecting mild dementia due to AD 
with 88% for sensitivity and 94% for specificity. De Bock et al. [60] concluded that 
EEG TsEn was an extremely promising potential diagnostic tool for mild cogni-
tive impairment (MCI) and early dementia with 82% for sensitivity and 73% for 
specificity. Al-Nuaimi et al. [34] discriminated AD patients with a sensitivity and 
specificity of 85.8 and 70.9% respectively from normal subjects using the TsEn 
method. Garn et al. [69] investigated the use of TsEn for the diagnosis of AD on the 
basis of an EEG analysis and obtained p-value <0.0036 for T7 and T8 channels for 
discrimination between AD patients and normal subjects.
HFD is a fast computing approach to obtain the fractal dimension of time series 
signals [70–72] even though there are very few data points available [70]. It can 
track changes in a biosignal from measuring its complexity [70, 71] and is appropri-
ate for capturing region-specific neural changes due to AD [43, 72]. Furthermore, 
HFD offers a precise measure of the complexity of the signal compared to other 
methods [44, 70, 73] and has been shown to be an effective approach to dis-
criminate between AD patients and normal subjects [30, 61]. HFD of the EEG is 
potentially a useful biomarker of AD diagnosis as it is significantly smaller in AD 
patients than in normal subjects [49, 61, 74]. Smits et al. [61] discovered that HFD 
Neuroimaging
4
is sensitive to neural changes selectively related in patients with AD and normal 
subjects. Al-nuaimi et al. [49] analyzed HFD of EEG for AD detection and discov-
ered that HFD is a promising EEG biomarker that captures changes in brain areas 
thought to be first affected by AD and could be used to identify AD with sensitivity 
and specificity values of 100 and 80% respectively.
LZC is a nonparametric and nonlinear method that provides a powerful method 
for quantifying the complexity of finite length sequences [75, 76]. It has previously 
been used to analyze EEG complexity in patients with AD [41, 77]. The reduction 
of LZC values may therefore be a good biomarker for AD [41, 77, 78]. It is a simple 
and powerful approach used in a number of biomedical applications [76]. LZC 
relies on coarse-grain measurement processing [77], and can be directly applied 
to the physiological signal without pre-processing [78]. LZC has been extensively 
used to measure the complexity of discrete-time physiological signals in the analysis 
of biomedical signals (e.g. EEG) [75]. It is also used in patients with AD to analyze 
brain function, transmission of brain information, and EEG complexity in patients 
with AD [41]. The LZC method produces a good biomarker for AD detection [78, 
79]. Using LZC in AD patients, Hornero et al. [80] analyzed EEG and magnetoen-
cephalogram (MEG). They discovered that LZC provides a useful insight into the 
EEG background activity features and the changes related to AD. Hornero et al. [81] 
discovered that LZC values were smaller in AD patients and proposed that the most 
significant differences were in the posterior region. In addition, they proposed that 
a reduced degree of irregularity and complexity characterize the MEG activity of 
AD patients and that LZC measurements can be used to identify AD patients with a 
sensitivity and specificity of 65 and 76.2% respectively. McBride et al. [62] inves-
tigated the complexity of EEG based on LZC approach for discriminating between 
patients with early cognitive impairment (MCI), AD patients and normal subjects. 
They discovered EEG complexity characteristics to provide promising results in dis-
criminating between MCI, AD, and normal subjects for particular EEG frequency 
bands with regional electrical activity. The complexity of MEG in MCI patients, 
AD patients and normal subjects was investigated by Fernandez et al. [82] based 
on the LZC approach of discriminating between the three groups. They discovered 
that they could differentiate between AD patients and MCI patients with 94.4% for 
sensitivity and specificity by combining age and posterior LZC scores.
2.2 Slowing of EEG
The slowing of the EEG is one of the most consistent features relating to the 
detection of AD. Slowing may therefore be quantified as a biomarker of AD [11, 37, 
83]. It can be measured in several ways such as changes in EEG amplitude (ΔEEGA), 
zero-crossing intervals (ZCI) [11], and changes in the power spectrum (ΔPS) of the 
EEG signal [11, 32, 33, 37, 39, 84–91]. Al-nuaimi et al. [5] quantified slowing in EEG 
by measuring the ΔEEGA. Their results showed that ΔEEGA is a promising nonlin-
ear EEG marker in the time domain. It can be measured through changes in EEG 
amplitude and can track changes in the EEG over time [5]. Their results showed that 
a gradual change in EEG amplitude is a marker for the subsequent rate of cognitive 
and functional decline in AD patients [5]. The reduction of ZCI of an EEG signal 
has also been shown to be a promising biomarker of AD [11, 74]. The slowing of the 
EEG can also be quantified by the power of the EEG signal in different frequency 
bands (i.e., delta, theta, alpha, beta, and gamma) where slowing is manifest in a 
decrease in power of high-frequency bands (alpha and beta) and an increase in 
power of low-frequency bands (delta and theta). These changes can be used to 
distinguish AD patients from those with other types of dementia [11, 32, 33, 37, 39]. 
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An increase in the power ratio of the alpha/middle alpha bands is an indicator of 
mild cognitive impairment (MCI) in people who may go on to develop AD [87]. 
Conversely, an increase in the power ratio of theta/gamma bands has been associ-
ated with MCI patients who may not develop AD [92]. This increase was related to a 
decline in memory and can therefore be used to identify MCI patients in a cohort of 
normal people [36]. Numerous studies have shown that power changes in the EEG 
frequency bands are promising markers of AD [84–91].
2.3 Reduction in EEG coherence
AD causes changes in the cortical activity of the brain [93] which impacts the 
connectivity among cortical regions of the brain [37], which can be reflected in 
the EEG coherence. EEG coherence can be quantified by assessing the functional 
coupling between brain regions [37, 94]. Coherence measures depend on channel 
location and the frequency bands of the EEG signal [93, 95–98]. Studies have shown 
that AD patients have a significant reduction in the coherence in the alpha band 
especially in the temporo-parieto-occipital regions and an increase in the coher-
ence in the delta band [93]. Furthermore, AD patients have a significant increase 
in the high beta band and a decrease in the delta band [99]. AD patients have also 
a reduction in both the left temporal alpha band and interhemispheric theta band 
compared to normal [97]. In addition, a positive association has been shown in EEG 
coherence in the frontal region for delta and beta bands [96]. The EEG coherence 
has been shown to be a sensitive and selective method for assessing the integrity of 
structural connections between brain areas in AD patients [98].
3. Discussions
Damage to nerve cells/pathways in the brain due to AD causes changes in the 
information-processing activity of the brain. These changes are thought to be 
reflected in the information content of the EEG. Therefore, each analysis technique 
of EEG signal may capture a different characteristic e.g., complexity, slowing, 
and coherence of the EEG signal. However, for each technique, there are different 
analysis methods and each method may measure a different feature that related to 
cognitive decline in the brain due to AD. Therefore, each method has a different 
performance. High-performance result referring the used techniques and biomark-
ers were accurate enough, this provides an indicator for using them in the future 
studies, and may also be possible to test the candidate biomarkers and techniques in 
regular health checkup performed by clinicians.
Unlike previous researches, Al-Nuaimi et al. [48], concluded that the complexity 
measures extracted from the EEG frequency bands (i.e. delta, theta, alpha, beta, 
and gamma) provide significantly better efficiency in the detection of AD than 
those extracted from the entire EEG record. This is due to the significant differences 
between the complexity measurements for AD patients and normal subjects when 
extracted from the frequency bands compared to the entire record, which is the 
desirable property of a good biomarker. In particular, they discovered that the best 
performance was provided by the complexity measurements extracted from the 
delta and gamma bands for TsEn and HFD. Three EEG channels (T4, O1, and O2) 
have provided the best performance for the delta band. While F4 has provided the 
best performance for the theta band.
Similar results for the LZC’s complexity measures were achieved, except that C3 
was the best EEG channel for the theta band. This is consistent with the results of 
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other researches proposing that AD starts at the back of the brain and then gradu-
ally extends to other areas of the brain [5, 49, 83, 100, 101]. This means that AD can 
be detected using only a small number of EEG channels.
Their results suggest that the three EEG complexity measures, derived from the 
EEG frequency bands, can detect AD reliably (with sensitivity and specificity of 
>90%). Thus, EEG complexity measures could provide a basis for developing an 
accurate, low-cost and easy use tool to detect AD.
They found that AD patients have significantly lower complexity measures for 
specific EEG frequency bands and for specific EEG channels than normal subjects. 
This is consistent with findings of in previous studies [32–34, 36–39]. Thus, specific 
EEG channels and specific frequency bands can be identified which can provide the 
best biomarkers for the detection of AD. This can be used to achieve good perfor-
mance in situations where the number of channels available is limited (e.g. when 
portable EEG systems are used outside specialist centers).
Al-nuaimi et al. [5] developed a new approach for detecting AD based on 
analyzing changes in EEG amplitude (ΔEEGA). Their results suggested that ΔEEGA 
is a promising biomarker for AD. As AD subjects have significantly lower ΔEEGA 
values., this provides an effective way to discriminate between AD patients and 
normal subjects. The reduction in ΔEEGA values is thought to be due to the slowing 
in the EEG as a result of AD and this is in keeping with the finding in other  
studies [102].
The findings of their studies have a number of implications for research to 
develop new and robust techniques for the analysis of EEG to increase the contribu-
tions EEG makes to the diagnosis of AD.
Several biomarkers were developed for AD diagnosis. However, some of these 
studies investigated the rationality of combining multiple biomarkers in one 
diagnostic index [2, 103–105]. Poil et al. [104] investigated the performance of 
six EEG based biomarkers separately and they combined them in one diagnostic 
model. They found, combining multiple biomarkers could be more sensitive for 
early diagnosis of AD. Polikar et al. [106] combined EEG, MRI and PET biomark-
ers. They suggested the combination of different biomarkers could improve the 
diagnostic accuracy over any of the individual data sources. Walhovd et al. [107] 
found combining MR and CSF biomarkers can improve diagnostic classification of 
AD. Consequently, combining multiple biomarkers from different analysis methods 
in one diagnostic index may assist to increase the diagnostic performance.
AD is the most common form of dementia and many dementia sufferers do not 
receive an early diagnosis. Currently, no specific device is available to diagnose 
AD. Therefore, developing new biomarkers or combining multiple biomarkers to 
produce a new biomarker with high performance may contribute to the develop-
ment of robust diagnosis methods that can be used to develop a new specific 
application for AD diagnosis in its early stages. Furthermore, early diagnosis of AD 
will contribute to the development of effective treatments that could slow, stop or 
prevent significant cognitive decline.
4. Conclusions
AD causes changes in the EEG due to memory loss and cognitive impairment, 
and these changes are thought to be associated with functional disconnections 
between cortical regions caused by brain cell death [37]. EEG assessment can, 
therefore, provide useful information on brain dynamics in AD. AD causes a 
decrease in brain neuronal activity that can be reflected in EEG signals. Non-linear 
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approaches based on EEG complexity methods showed promising results in the 
detected EEG changes that were thought to be due to AD [5, 34, 48, 49].
EEG based biomarkers can be used as the first line of decision making because 
these biomarkers are non-invasive, and low cost compared to others e.g., CSF, 
MRI or PET. However, EEG based biomarkers can complement other biomarkers 
[25, 106, 108].
EEG based biomarkers to detect AD have some limitations such as the size of 
samples were used in each study. Most of the EEG studies used a data sized between 
10 and 100 of samples [109], unlike the MRI biomarkers, have thousands of samples 
available with free access as shown in ADNI dataset [4]. Most of the used EEG 
samples are cross-section, not a longitudinal dataset, and not free access to EEG 
datasets of AD. To overcome those limitations, longitudinal EEG dataset of AD may 
assist to track the dynamic changes in the brain which caused by AD, a large number 
of EEG sample may help to add more reality to the results, and free access to EEG 
dataset of AD will minimize the burden that researchers spent in collecting the 
dataset.
In this study, we reviewed an important class of complexity measures, informa-
tion-theoretic methods, which offers a potentially powerful approach for quan-
tifying changes in the EEG due to AD [59]. Information-theoretic methods have 
emerged as a potentially useful complexity-based approach to derive robust EEG 
biomarkers of AD [50, 59, 60, 65, 110, 111]. They are attractive due to the potential 
natural connection between biomarkers based on information theory and brain 
changes induced by AD [59]. Conceptually, information-processing activities in the 
brain are considered to be reflected in the information content of the EEG.
As a result, EEG complexity can potentially be a useful biomarker for the 
diagnosis of AD. We examined the three complexity measures approached by TsEn, 
HFD, and LZC extracted from the EEG frequency bands. TsEn, HFD, and LZC 
values in AD patients were found to be significantly lower in AD patients than in 
normal subjects for specific EEG frequency bands and specific EEG channels.
This study demonstrates that the complexity measures can detect the abnormali-
ties induced by AD. However, other neurodegenerative diseases, such as other kinds 
of dementia, may cause similar changes. To improve the diagnostic usefulness of the 
methods, further development may be necessary to distinguish between dementias.
The slowing of the EEG was also reviewed. It is one of the most consistent 
features relating to the detection of AD. The slowing of EEG may therefore be quan-
tified as a biomarker of AD [11, 37, 83].
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